{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:49:34Z","timestamp":1780580974192,"version":"3.54.1"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1111\/ijcp.13030","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T08:56:37Z","timestamp":1507798597000},"page":"e13030","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?"],"prefix":"10.1155","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[{"name":"New York Medical College; Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"10.1111\/ijcp.13030-BIB0001|ijcp13030-cit-0001","unstructured":"Teva Pharmaceuticals AUSTEDO (deutetrabenazine) tablets, for oral use. Prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209885lbl.pdf"},{"key":"10.1111\/ijcp.13030-BIB0002|ijcp13030-cit-0002","unstructured":"Neurocrine Biosciences INGREZZA (valbenazine) capsules, for oral use. Prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209241lbl.pdf"},{"key":"10.1111\/ijcp.13030-BIB0003|ijcp13030-cit-0003","unstructured":"Lundbeck XENAZINE (tetrabenazine) tablets, for oral use. Prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021894s010lbl.pdf"},{"key":"10.1111\/ijcp.13030-BIB0004|ijcp13030-cit-0004","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","article-title":"Deutetrabenazine in Tics Associated with Tourette Syndrome","volume":"6","author":"Jankovic","year":"2016","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1111\/ijcp.13030-BIB0005|ijcp13030-cit-0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0006|ijcp13030-cit-0006","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0007|ijcp13030-cit-0007","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0008|ijcp13030-cit-0008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1111\/ijcp.13030-BIB0009|ijcp13030-cit-0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0010|ijcp13030-cit-0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0011|ijcp13030-cit-0011","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0012|ijcp13030-cit-0012","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1345\/aph.1P312","article-title":"Tetrabenazine for the treatment of tardive dyskinesia","volume":"45","author":"Leung","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1111\/ijcp.13030-BIB0013|ijcp13030-cit-0013","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ijcp.12805","article-title":"Breakthrough drugs for the interface between psychiatry and neurology","volume":"70","author":"Citrome","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.13030-BIB0014|ijcp13030-cit-0014","doi-asserted-by":"crossref","first-page":"e12964","DOI":"10.1111\/ijcp.12964","article-title":"Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"71","author":"Citrome","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.13030-BIB0015|ijcp13030-cit-0015","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"10.1111\/ijcp.13030-BIB0016|ijcp13030-cit-0016","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0017|ijcp13030-cit-0017","first-page":"S158","article-title":"Effect of deutetrabenazine on quality of life in patients with tardive dyskinesia in AIM-TD, a 12-week double-blind, placebo-controlled study","volume":"32","author":"Factor","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0018|ijcp13030-cit-0018","first-page":"S157","article-title":"Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study","volume":"32","author":"Anderson","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0019|ijcp13030-cit-0019","first-page":"S156","article-title":"Effect of deutetrabenazine on QTcF interval in the AIM-TD study: A 12-week, phase III, randomized, double-blind, placebo-controlled study","volume":"32","author":"Anderson","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0020|ijcp13030-cit-0020","first-page":"S161","article-title":"Effect of deutetrabenazine by body region score of the abnormal involuntary movement scale in tardive dyskinesia: ARM-TD and AIM-TD studies","volume":"32","author":"Fernandez","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0021|ijcp13030-cit-0021","first-page":"S160","article-title":"Addressing involuntary movements in tardive dyskinesia (AIM-TD): improvements in clinical global impression of change (CGIC) with deutetrabenazine treatment in tardive dyskinesia (TD)","volume":"32","author":"Jimenez-Shahed","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0022|ijcp13030-cit-0022","first-page":"S159","article-title":"Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials","volume":"32","author":"Fernandez","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0023|ijcp13030-cit-0023","first-page":"S159","article-title":"Deutetrabenazine treatment response by concomitant dopamine-receptor antagonists in the phase III, randomized, double-blind, placebo-controlled AIM-TD trial in tardive dyskinesia","volume":"32","author":"Jimenez-Shahed","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0024|ijcp13030-cit-0024","first-page":"S158","article-title":"Improvements in clinical global impression of change with deutetrabenazine treatment in tardive dyskinesia from the ARM-TD and AIM-TD studies","volume":"32","author":"Fernandez","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0025|ijcp13030-cit-0025","doi-asserted-by":"crossref","first-page":"S56.006","DOI":"10.1212\/WNL.88.16_supplement.S56.006","article-title":"Addressing involuntary movements in tardive dyskinesia (AIM-TD): Effect of fixed-dose deutetrabenazine by baseline comorbidities","volume":"88","author":"Anderson","year":"2017","journal-title":"Neurology"},{"key":"10.1111\/ijcp.13030-BIB0026|ijcp13030-cit-0026","first-page":"S355","article-title":"A randomized double-blind placebo-and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval","volume":"31","author":"Stamler","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0027|ijcp13030-cit-0027","doi-asserted-by":"crossref","first-page":"P1.054","DOI":"10.1212\/WNL.86.16_supplement.P1.054","article-title":"A relative bioavailability study of three dose strengths and four dose levels of SD-809, a potential treatment for movement disorders","volume":"86","author":"Stamler","year":"2016","journal-title":"Neurology"},{"key":"10.1111\/ijcp.13030-BIB0028|ijcp13030-cit-0028","first-page":"S271","article-title":"The pharmacokinetics of extended release SD-809, a deuterium-substituted analogue of tetrabenazine","volume":"28","author":"Stamler","year":"2017","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0029|ijcp13030-cit-0029","doi-asserted-by":"crossref","first-page":"P07.210","DOI":"10.1212\/WNL.80.7_supplement.P07.210","article-title":"The pharmacokinetics and safety of deuterated-tetrabenazine","volume":"80","author":"Stamler","year":"2013","journal-title":"Neurology"},{"key":"10.1111\/ijcp.13030-BIB0030|ijcp13030-cit-0030","unstructured":"Jimenez-Shahed J Factor SA Ondo WG Deutetrabenazine is associated with an improvement in involuntary movements in patients with tardive dyskinesia (TD) as seen by the high proportion of responders to treatment in the ARM-TD study San Antonio, Texas"},{"key":"10.1111\/ijcp.13030-BIB0031|ijcp13030-cit-0031","unstructured":"Anderson K Stamler D Davis M Deutetrabenazine for the treatment of tardive dyskinesia: results from an open-label, long-term study San Diego, California"},{"key":"10.1111\/ijcp.13030-BIB0032|ijcp13030-cit-0032","unstructured":"Fernandez HH Factor SA Jimenez-Shahed J The effect of deutetrabenazine on individual components of the total abnormal involuntary movement scale (AIMS) in ARM-TD San Diego, California"},{"key":"10.1111\/ijcp.13030-BIB0033|ijcp13030-cit-0033","unstructured":"Auspex Pharmaceuticals Treating hyperkinetic movement disorders http:\/\/files.shareholder.com\/downloads\/AMDA-2IEHYZ\/0x0x797219\/01a86e01-44d4-4ee0-9fb2-69537c486954\/Piper%20Jaffray%20Presentation%2012-2-14.pdf"},{"key":"10.1111\/ijcp.13030-BIB0034|ijcp13030-cit-0034","unstructured":"US Food and Drug Administration Austedo (deutetrabenazine) tablets. drug approval package https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208082Orig1s000TOC.cfm"},{"key":"10.1111\/ijcp.13030-BIB0035|ijcp13030-cit-0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/ijcp.13030-BIB0036|ijcp13030-cit-0036","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ijcp.13030-BIB0037|ijcp13030-cit-0037","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.13030-BIB0038|ijcp13030-cit-0038","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/13543776.2014.943184","article-title":"Deuterated drugs: where are we now?","volume":"24","author":"Timmins","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"10.1111\/ijcp.13030-BIB0039|ijcp13030-cit-0039","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/jm4007998","article-title":"Using deuterium in drug discovery: leaving the label in the drug","volume":"57","author":"Gant","year":"2014","journal-title":"J Med Chem"},{"key":"10.1111\/ijcp.13030-BIB0040|ijcp13030-cit-0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd.2016.63","article-title":"Deuterated drugs draw heavier backing","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/ijcp.13030-BIB0041|ijcp13030-cit-0041","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4155\/fmc-2016-0032","article-title":"Deuterium medicinal chemistry comes of age","volume":"8","author":"Tung","year":"2016","journal-title":"Future Med Chem"},{"key":"10.1111\/ijcp.13030-BIB0042|ijcp13030-cit-0042","first-page":"8","article-title":"Deuterium medicinal chemistry: a new approach to drug discovery and development","volume":"24","author":"Harbeson","year":"2014","journal-title":"Medchem News"},{"key":"10.1111\/ijcp.13030-BIB0043|ijcp13030-cit-0043","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0165-6147(84)90534-0","article-title":"Deuterium isotope effects in studies of drug metabolism","volume":"5","author":"Foster","year":"1984","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/ijcp.13030-BIB0044|ijcp13030-cit-0044","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jlcr.3031","article-title":"Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions","volume":"56","author":"Guengerich","year":"2013","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1111\/ijcp.13030-BIB0045|ijcp13030-cit-0045","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","article-title":"Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites","volume":"361","author":"Grigoriadis","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/ijcp.13030-BIB0046|ijcp13030-cit-0046","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Kantrowitz. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"J Expert Rev Neurother"},{"key":"10.1111\/ijcp.13030-BIB0047|ijcp13030-cit-0047","first-page":"1","article-title":"Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders","volume":"13","author":"Citrome","year":"2007","journal-title":"Am J Manag Care"},{"key":"10.1111\/ijcp.13030-BIB0048|ijcp13030-cit-0048","first-page":"A189","article-title":"Feasibility of a comparative meta-analysis of VMAT2 inhibitors for the treatment of tardive dyskinesia","volume":"20","author":"Caroff","year":"2017","journal-title":"Value Health"},{"key":"10.1111\/ijcp.13030-BIB0049|ijcp13030-cit-0049","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mdc3.12483","article-title":"Tetrabenazine versus deutetrabenazine for Huntington's disease: twins or distant cousins?","volume":"4","author":"Rodrigues","year":"2017","journal-title":"Movement Disord Clin Pract (Hoboken, NJ)"},{"key":"10.1111\/ijcp.13030-BIB0050|ijcp13030-cit-0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J Clin Mov Disord"},{"key":"10.1111\/ijcp.13030-BIB0051|ijcp13030-cit-0051","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.13030-BIB0052|ijcp13030-cit-0052","unstructured":"US Food and Drug Administration NDA 209885. NDA approval letter https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/209885Orig1s000ltr.pdf"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.13030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijcp.13030\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T10:25:40Z","timestamp":1750933540000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.13030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.13030","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}